Dominion Capital LLC Sample Contracts
AGREEMENTInvestment Agreement • October 5th, 2020 • Dominion Capital L.L.C. • Pharmaceutical preparations
THIS AGREEMENT, dated as of October 2, 2020, (the “Agreement”) is by and between Dominion Capital LLC (“Dominion”), Anson Investments Master Fund LP (“AIMF”) and Lorient Ventures Ltd.
FORBEARANCE AND SETTLEMENT AGREEMENTForbearance and Settlement Agreement • April 23rd, 2025 • Dominion Capital LLC • Computer communications equipment
This FORBEARANCE AND SETTLEMENT AGREEMENT (this “Agreement”) is entered into as of this 20th day of February 2025 (the “Effective Date”), by and Dominion Capital LLC (“Dominion”) and HUB Cyber Security Ltd. (“HUB”). Dominion and HUB shall be referred to collectively herein as the “Parties” and each, individually, as a “Party”).
Joint Filing AgreementJoint Filing Agreement • March 18th, 2024 • Dominion Capital L.L.C. • Computer communications equipment
In accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, the persons and entities named below agree to the joint filing on behalf of each of them of the foregoing Schedule 13D with respect to the ordinary shares, no par value per share, of Hub Cyber Security Ltd., and that all subsequent amendments to such Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned hereby further agree that this joint filing agreement be included as an exhibit to such Schedule 13D and that this joint filing agreement may be executed in any number of physical or electronically signed counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument. In evidence thereof, the undersigned, being duly authorized, have executed this joint filing agreement as of March 18, 2024.
ASSIGNMENT AGREEMENTAssignment Agreement • April 23rd, 2025 • Dominion Capital LLC • Computer communications equipment
This Assignment Agreement (the “Agreement”) is made by and between Claymore Capital Pty Ltd. (the “Assignee”) and Dominion Capital LLC (the “Assignor”), effective February 20, 2025. The Assignor and the Assignee are sometimes referred to in this Agreement singly as a “Party” or collectively as the “Parties”.
JOINT FILING AGREEMENTJoint Filing Agreement • October 5th, 2020 • Dominion Capital L.L.C. • Pharmaceutical preparations
This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)Joint Filing Agreement • October 1st, 2025 • Dominion Capital LLC • Services-health services
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned with respect to shares of common stock of par value $0.0001 per share, of VSee Health, Inc. (CUSIP 92919Y102) and that all subsequent amendments to such statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall b
Joint Filing AgreementJoint Filing Agreement • January 7th, 2025 • Dominion Capital LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, the persons and entities named below agree to the joint filing on behalf of each of them of the foregoing Schedule 13D with respect to the shares of common stock, par value $0.001 per share, of ReShape Lifesciences, Inc, and that all subsequent amendments to such Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned hereby further agree that this joint filing agreement be included as an exhibit to such Schedule 13D and that this joint filing agreement may be executed in any number of physical or electronically signed counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument. In evidence thereof, the undersigned, being duly authorized, have executed this joint filing agreement as of January 7, 2025.